Health and Me on MSN1d
Yearly Jab For HIV Protection Is Now Almost Here
A yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making ...
The Lancet5d
The potential for annual long-acting HIV pre-exposure prophylaxis
Pre-exposure prophylaxis (PrEP) is the advent of antiretroviral treatment use for people at increased risk of acquiring HIV-1 ...
The American Journal of Managed Care4d
Long-Acting Injectable Cabotegravir Effective in Both ART, PrEP
Cabotegravir was found to prevent HIV acquisition as a monotherapy pre-exposure prophylaxis (PrEP) and to treat HIV as a ...
The Washington Informer4d
Empowering Women and Girls: Advancing HIV Prevention
March is a significant month for women's health, observing International Women's Day and National Women's HIV/AIDS Awareness ...
The Scientist4d
Gilead’s Capsid Revolution Meets Our Capsid Solutions: Sino Biological – Engineering the Tools to Outsmart HIV
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...
BlackDoctor.org2d
Preparing for PrEP Side Effects
Like most prescribed medications, all three brands PrEP brands feature side effects. Here's how to prepare for them.
BioSpace4d
Gilead, GSK-ViiV Move Ahead With Long-Acting HIV Options Following Early-Stage Readouts
Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...
STAT5d
Gilead data suggest once-yearly shot of PrEP drug blocks HIV infection
Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...